We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

1 hedge funds and large institutions have $10.2K invested in Apellis Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 279 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 323 → 1 (-322)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $5.56B → $10.2K (-$5.56B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 279

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

109.78% less ownership

Funds ownership: 109.78% → 0% (-110%)

Holders
1
Holders Change
-322
Holders Change %
-99.69%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
279
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$545M
2
ACA
Avoro Capital Advisors
New York
-$492M
3
Morgan Stanley
Morgan Stanley
New York
-$404M
4
State Street
State Street
Massachusetts
-$275M
5
UBS Group
UBS Group
Switzerland
-$250M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
– -$37.7M -935,958 Closed
Marshall Wace
27
Marshall Wace
United Kingdom
– -$37.4M -929,019 Closed
Man Group
28
Man Group
United Kingdom
– -$36.8M -915,689 Closed
First Trust Advisors
29
First Trust Advisors
Illinois
– -$36.4M -903,637 Closed
MF
30
Magnetar Financial
Illinois
– -$35M -869,229 Closed
AAM
31
Alpine Associates Management
Florida
– -$34.8M -864,000 Closed
OBAM
32
ODDO BHF Asset Management
France
– -$33.2M -825,000 Closed
Northern Trust
33
Northern Trust
Illinois
– -$29.7M -738,440 Closed
WAM
34
Weiss Asset Management
Massachusetts
– -$28.2M -700,000 Closed
Charles Schwab
35
Charles Schwab
California
– -$27.2M -675,864 Closed
Citigroup
36
Citigroup
New York
– -$26.4M -657,223 Closed
Vanguard Fiduciary Trust
37
Vanguard Fiduciary Trust
Pennsylvania
– -$26.3M -654,922 Closed
AllianceBernstein
38
AllianceBernstein
Tennessee
– -$16M -638,291 Closed
BNP Paribas Financial Markets
39
BNP Paribas Financial Markets
France
– -$23.5M -584,192 Closed
O
40
Ossiam
France
– -$22.4M -555,953 Closed
Bank of New York Mellon
41
Bank of New York Mellon
New York
– -$21.1M -524,789 Closed
Two Sigma Investments
42
Two Sigma Investments
New York
– -$21M -521,965 Closed
Principal Financial Group
43
Principal Financial Group
Iowa
– -$20.1M -499,053 Closed
Squarepoint
44
Squarepoint
New York
– -$18.1M -449,796 Closed
Invesco
45
Invesco
Georgia
– -$17.6M -437,868 Closed
Pictet Asset Management
46
Pictet Asset Management
Switzerland
– -$7.56M -426,821 Closed
LP
47
LMR Partners
United Kingdom
– -$16.2M -403,622 Closed
Verition Fund Management
48
Verition Fund Management
Connecticut
– -$16.1M -400,000 Closed
Public Sector Pension Investment Board (PSP Investments)
49
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
– -$14.8M -366,674 Closed
FTCM
50
First Trust Capital Management
Illinois
– -$14.1M -350,800 Closed
1
2
3 4 5

APLS Hedge Fund Activity: Q2 2026 in Review

1 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2026, worth a combined $10.2K — down 100% from $5.56B a quarter earlier.

Sellers outnumbered buyers: 279 funds closed out of APLS and 0 opened new positions — a net loss of 279 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $545M sold.

  • 1 institutional investor held Apellis Pharmaceuticals (APLS) as of Q2 2026, down from 323 in Q1 2026.
  • Funds reported $10.2K of Apellis Pharmaceuticals stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Apellis Pharmaceuticals positions in Q2 2026 and 279 closed out, a net change of -279 holders.
  • The largest Apellis Pharmaceuticals seller in Q2 2026 was BlackRock, an estimated $545M sold.

Based on aggregated 13F filings for Q2 2026.